On February 7th, at the beginning of the new year, EMICRO Biomedicine brought exciting news. In the Phase I clinical trial of its BTK inhibitor lymphoma project, for the second patient (with refractory and relapsed follicular lymphoma), after two months of administration at a 100 - mg dose, the tumor efficacy assessment showed not only good safety and tolerability, but also that the patient's lymphoma lesion was reduced by 82.91%.

With the patient taking only this single drug, the BTK inhibitor of EMICRO Biomedicine has achieved such excellent clinical treatment results. In the field of innovative drugs, it has set a good precedent for a successful start in 2025 in Xinxiang and even Henan Province. For the first lymphoma patient enrolled in EMICRO Biomedicine's project, after taking the lowest dose (50mg) for two months, the tumor efficacy assessment on December 27, 2024, indicated that the lymphoma lesion was reduced by 51%. Currently, the BTK inhibitor lymphoma project of EMICRO Biomedicine is being carried out in an orderly manner at Peking University Cancer Hospital, the First Affiliated Hospital of Zhengzhou University, Henan Cancer Hospital, and the First People's Hospital of Chenzhou. As of now, 4 patients have been enrolled, and they have all shown good reactions after taking the drug.